120 West 45th Street
17th Floor, Tower 45
25 articles with Schrödinger Inc
Schrödinger announced the appointment of Nancy Thornberry, a biotech executive recognized for her extensive track record in drug discovery and development, to its Board of Directors.
Schrödinger Announces Expansion of Multi-Target Research Collaboration with Takeda and Achievement of First Significant Preclinical Milestone in Lead Program
Schrödinger announced the expansion of its multi-year, multi-target drug discovery collaboration with Takeda, as well as Schrödinger’s achievement of the first significant preclinical milestone for the collaboration’s most advanced program.
Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery
Schrödinger announced a collaboration with AstraZeneca to deploy Schrödinger’s advanced computing platform to help accelerate drug discovery efforts.
Schrödinger and Qu & Co Announce Collaboration to Advance Quantum Mechanical Computations on Quantum Computers
Schrödinger and Qu & Co announced a business and scientific collaboration to advance the use of quantum mechanics on complex molecular systems using quantum computing hardware.
Extended collaboration leveraging Schrödinger’s computational platform includes new terms with increased and additional milestone payments to Schrödinger
Mr. Sender brings over 30 years of financial leadership experience, with a strong track record of success.
Schrödinger announced receipt of a milestone payment from Ono Pharmaceutical Co., Ltd. as part of a collaboration leveraging Schrödinger’s advanced computational platform to develop novel therapeutic candidates acting on the therapeutic target selected by Ono.
Milestone marks advancement of second drug discovery program under the collaboration
New hires to lead ADME/PK and Clinical Pharmacology for rapidly advancing internal pipeline programs
New funding to support platform advancements and proprietary pipeline expansion
Schrödinger announced that the Company will be presenting on its advanced computational platform, which integrates physics-based molecular simulation and machine learning to accelerate drug discovery, at the upcoming conferences in May
The companies are currently advancing programs in oncology and autoimmune disease.
Schrödinger announced the appointment of Professor of Chemistry Brian Shoichet, Ph.D., a widely published thought leader in the field of computational drug discovery, to its scientific advisory board.
Schrödinger today announced the appointment of veteran biotech leader Rosana Kapeller, M.D., Ph.D., to its board of directors.
Schrödinger Closes $85 Million Financing to Advance Computational Platform and Expand Drug Discovery Pipeline
Investment in R&D will extend capabilities of computational platform and support growth of partnered and proprietary programs
Partnership merges Schrödinger’s advanced modeling capabilities with TB Alliance’s expertise in tuberculosis biology to accelerate the development of next-generation treatments
Schrödinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program
Collaboration brings together Schrödinger’s in silico discovery capabilities with SPARC’s novel insights into CNS pathways to speed drug development
11/19/2018Companies bolstered their leadership with additions to boards of directors and c-suite offices.
Mr. Lebowitz, a longtime senior executive at Merck, brings to the company deep experience in finance and business development.
Schrödinger and WuXi AppTec Announce the Launch of Faxian Therapeutics to Enable Accelerated Drug Discovery
The new venture will leverage the precision molecular design platforms developed by Schrödinger and accelerate them through partnership with the world-class lead optimization services provided by WuXi AppTec.